ASX 200 Biotech Watch: Telix’s ProstACT Trial and Valuation

Highlights

• Telix Pharmaceuticals advances Part 2 of its ProstACT Global Phase 3 trial

• Revenue growth and pipeline progress contrast with a softer share price

• Valuation appears discounted to some models, yet clinical and execution risks remain

Telix Pharmaceuticals advances its ProstACT Global Phase 3 trial while trading at a discount to several valuation lenses, leaving the market to weigh maturing radiopharma potential against familiar clinical and execution risks.

Telix Pharmaceuticals Limited (ASX:TLX) has reached another important staging post in its prostate cancer program, dosing the first patient in Part 2 of the ProstACT Global Phase 3 trial for TLX591 while remaining a recognised name within the ASX 200. For a radiopharmaceutical business already generating revenue yet still deeply tied to clinical outcomes, this moment crystallises a familiar question on the ASX stock market: is the current share price underestimating a maturing pipeline, or correctly balancing opportunity against the realities of late-stage oncology development?

Who is Telix and what makes its model different?

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company specialising in diagnostic and therapeutic radiopharmaceuticals, often described under the umbrella of “theranostics” because the same biological targets can guide both imaging and treatment.

Instead of traditional small-molecule pills or monoclonal antibodies without radioisotopes, Telix pairs targeting agents with radioactive payloads that can:

• illuminate tumours for more accurate imaging

• deliver focused radiation to cancer cells while limiting exposure to surrounding tissue

The company’s core portfolio spans urologic cancers such as prostate and kidney, neuro-oncology, musculoskeletal tumours and selected haematologic indications, supported by an international footprint across Australia, Europe, the Americas and Asia.

This positioning places Telix at the intersection of oncology, nuclear medicine and precision imaging, in contrast to many conventional ASX ordinaries stocks whose value is tied more directly to macro cycles, consumer demand or commodity prices.

What is TLX591 and why does ProstACT Global matter?

TLX591 is Telix’s lead therapeutic candidate for advanced prostate cancer, a radio-antibody drug conjugate that targets prostate-specific membrane antigen (PSMA). By binding selectively to PSMA-expressing cells and delivering a lutetium-based radioactive payload, TLX591 aims to damage cancer tissue while reducing collateral impact on healthy areas.

The ProstACT Global trial is an international Phase 3 study designed to test TLX591 in combination with standard of care (such as androgen-receptor pathway inhibitors or chemotherapy) versus standard care alone in metastatic castration-resistant prostate cancer.

Key features of ProstACT Global include:

• A two-part structure: Part 1 as a safety and dosimetry lead-in, now completed, and Part 2 as a randomised treatment expansion

• Randomisation in Part 2 comparing TLX591 plus standard therapy against standard therapy alone

• Recruitment across multiple regions, including Australia, New Zealand, North America and other international sites as regulatory approvals progress

Dosing the first patient in Part 2 signals that the program has moved beyond early safety work and into the more decisive phase where efficacy, safety and real-world treatment combinations will be scrutinised at scale.

Why has sentiment weakened despite solid progress?

The recent update on ProstACT Global arrives after a difficult period for the share price, which has declined over the current year even though the three-year total return remains strongly positive. This divergence suggests the market is recalibrating expectations around Telix’s growth trajectory, balancing:

• a now-commercial platform with meaningful revenue and profit growth in place

• a late-stage pipeline that still carries clinical and regulatory uncertainty

• a valuation that screens cheaper than many peers on certain metrics

In other words, the story looks more mature and less speculative than in earlier years, but investors remain wary about how long high growth can be maintained and how smoothly trials like ProstACT Global will progress.

How does the current valuation stack up?

A closer look at the price-to-sales lens

On a price-to-sales basis, Telix currently trades at a multiple in the mid-single digits, below many domestic biotech comparables and international peers that command double-digit ratios. External analysis has highlighted that this gap implies a market discount to Telix’s growth profile and late-stage pipeline, particularly given that the company is already commercial with expanding revenue.

For a commercial-stage biotech, price-to-sales can be a useful sanity check because:

• earnings can be noisy as pipeline programs ramp and investment cycles shift

• revenue from approved products provides a tangible base against which to judge expectations

• large discrepancies versus peer groups may signal either opportunity or unrecognised risk

In Telix’s case, the comparatively low multiple suggests that investors are paying less for each dollar of current sales than they do for many other healthcare names, even within the innovative healthcare and biotech cohort.

What about discounted cash flow models?

Discounted cash flow (DCF) approaches, which project future cash streams and adjust them back to present value, also point to upside in several independent models monitoring Telix, with estimated fair values materially above the current share price.

When both sales-based and cash-flow-based frameworks suggest that the market price sits below modelled intrinsic ranges, two interpretations naturally arise:

• the market may be underestimating how durable Telix’s revenue and earnings growth could be if key programs succeed; or

• models may underestimate the probability or impact of adverse clinical, regulatory or competitive developments.

Valuation, in other words, is signalling potential misalignment between current price and some fundamental scenarios, but those scenarios hinge on assumptions about trial outcomes and adoption curves that are still being tested in real time.

What are the main risks the market is weighing?

Clinical and regulatory risk

Late-stage oncology programs carry inherent uncertainty. Even when early-stage data are encouraging, larger Phase 3 studies can uncover safety signals, mixed efficacy or subgroup dynamics that complicate regulatory paths. For TLX591 and ProstACT Global, key questions include:

• whether the combination with standard care delivers a clear benefit on progression-focused endpoints

• how tolerable the therapy is at scale across diverse patient populations

• how regulators in major markets interpret the overall benefit-risk profile

Any setback, delay or ambiguous outcome in ProstACT Global could quickly alter the perceived value of this cornerstone asset.

Competitive landscape in radiopharma

Radiopharmaceuticals have become a more crowded field, with large global players already marketing PSMA-targeted therapies and imaging agents. Telix is positioning TLX591 as a differentiated antibody-based approach, potentially offering a distinct balance of dosing convenience, targeting and safety.

However, the presence of strong competitors means:

• payers and clinicians will compare efficacy, safety, logistics and cost across options

• speed to market and breadth of indications will matter

• follow-on innovations could change the standard of care before Telix fully captures its opportunity

Execution and scale-up risk

As a business in transition from development to broader commercialisation, Telix faces operational challenges common across innovative ASX 100 and mid-cap healthcare names:

• scaling manufacturing and supply chains for complex radio-based products

• building and supporting specialised distribution networks and treatment centres

• maintaining compliance across multiple jurisdictions with different regulatory frameworks

These execution factors interact with trial progress and competitive dynamics to shape long-term margin structures and cash generation.

How does Telix fit into a broader portfolio context?

Telix’s profile is very different from income-oriented names often grouped under ASX dividend stocks. The company reinvests heavily in clinical programs, manufacturing capability and geographic expansion, meaning cash flows are directed towards growth rather than high near-term distributions.

Within the ASX 200 healthcare segment, Telix stands out as:

• a commercial-stage radiopharmaceutical business with both imaging and therapeutic products

• an active participant in precision oncology, particularly in urologic cancers

• a company whose share price can react sharply to clinical news, regulatory events and updates on key trials like ProstACT Global

For market watchers, Telix can serve as a case study in how innovative therapies migrate from concept to clinic, and how valuation can fluctuate as perception shifts from blue-sky potential to data-driven assessment.

Has the “bull case” for Telix really changed?

At its core, the positive narrative around Telix has always centred on a few pillars:

• a differentiated position in radiopharmaceuticals across imaging and therapy

• a lead prostate cancer candidate with late-stage potential in a large indication

• a revenue base from approved products that helps support ongoing development

• a pipeline extending beyond a single program into other cancer areas

Dosing the first patient in Part 2 of ProstACT Global strengthens the argument that Telix is progressing towards pivotal data in its flagship indication. At the same time, a softer share price and discounted valuation metrics indicate the market is demanding more proof that this pipeline can translate into sustained cash flows over many years.

In that sense, the core thesis has evolved rather than flipped. The company is no longer a pre-revenue aspirant; it is a commercial-stage radiopharma player with a meaningful clinical and manufacturing footprint. But that evolution brings a new balance of expectations: less tolerance for delays or mixed data, and greater scrutiny of execution, competition and capital discipline.

Whether the current price reflects caution or opportunity will ultimately hinge on the results emerging from ProstACT Global and other key programs — and on how effectively Telix can scale a complex, precision-driven business model within the broader currents of global oncology innovation.